
News|Articles|November 1, 2002
From the MTIRS: Anticonvulsant reduces migraine headache frequency
A phase III study presented at the 14th annual meeting of the Migraine Trust International Research Symposium (MTIRS) in September in London showed that topiramate (Topamax) significantly reduced migraine frequency at doses as low as 100 mg/d. The onset of efficacy was observed as early as the first month of treatment. Topiramate is already approved in the United States and worldwide as an
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers
2
The MASLD-breast cancer connection
3
Transforming care through social determinants of health
4
FDA approves Lumvoa, first TED therapy labeled for both active and chronic disease
5






























